Androgen-Deprivation Therapy and Risk for Colorectal Cancer

Androgen-deprivation therapy (ADT) is the standard initial treatment for men with metastatic prostate cancer, yet the majority of men in the U.S. who receive ADT have nonmetastatic disease. Recently, the FDA asked the manufacturers of gonadotropin-releasing hormone (GnRH) agonists to include warnings about the potential risks for diabetes and cardiovascular diseases associated with their products; links between GnRH agonists and fracture risk have also been demonstrated (JW Oncol Hematol Aug 11 2009).

Now, investigators have assessed the potential association between colorectal cancer (CRC) and the use of ADT (with GnRH agonists or orchiectomy). The researchers analyzed Surveillance, Epidemiology, and End Results (SEER) Medicare data for 107…